S3788-119

What This Bill Does

The reported CLEAR LABELS Act bars introduction into interstate commerce of an active pharmaceutical ingredient unless its label and certificate of analysis name the original manufacturer and place of business. A packaged finished drug must identify, on the label or electronically, the original manufacturer of every active ingredient, the original finished-drug manufacturer, and any packer or distributor. Where a lot may use multiple original ingredient manufacturers, each applicable manufacturer must be identified. An original manufacturer is the establishment conducting the majority of significant chemical, physical, or biological manufacturing phases for the ingredient or dosage form. FDA may treat noncompliance as misbranding and impose a civil monetary penalty, but may not treat it as a criminal violation. The penalty may not exceed 25 percent of the value of affected lots; FDA must consider business size, violation gravity, advance written notice and opportunity to cure, and good-faith correction. FDA and Customs and Border Protection must coordinate to reduce overlap or conflict with customs country-of-origin marking, potentially through information sharing or joint rulemaking. Existing trade-secret and confidential-information protections remain. The requirements apply to ingredients and drugs manufactured and packaged five years after enactment. Compared with the introduced bill, the reported substitute drops unique facility identifiers, mandatory paper copies and the direct customs-marking exemption, uses a different manufacturing test, delays applicability to five years, and expressly limits enforcement to discretionary civil consequences.

Who Benefits and How

Patients, clinicians, pharmacies, purchasers, FDA, and Customs gain clearer information about the establishments responsible for active ingredients and finished dosage forms. Legitimate manufacturers may distinguish their supply chains from opaque or unreliable sources. Small and compliant manufacturers benefit from penalty factors requiring consideration of business size, notice, cure opportunity, and good faith. Firms also benefit from a five-year implementation period, electronic disclosure options, confidentiality protections, and agency coordination intended to avoid duplicative federal marking duties.

Who Bears the Burden and How

Ingredient manufacturers, finished-drug manufacturers, packers, and distributors must map lot-level original manufacturing relationships, update labels and certificates, maintain electronic information where used, and manage supplier changes. Noncompliance can expose a person to misbranding treatment and penalties up to 25 percent of lot value. FDA must interpret original manufacturer, oversee compliance, make discretionary enforcement and penalty decisions, and protect confidential records. FDA and Customs must coordinate potentially overlapping labeling and country-of-origin systems and may conduct joint rulemaking.

Key Provisions

• Requires active-ingredient labels and certificates to identify the original manufacturer and business location.
• Requires packaged finished-drug labels or electronic information to identify ingredient, finished-product, packing, and distribution parties.
• Defines original manufacturer by the majority of significant manufacturing phases.
• Authorizes discretionary misbranding treatment and civil penalties up to 25 percent of affected lot value.
• Requires consideration of business size, gravity, notice, cure opportunity, and good-faith correction.
• Requires FDA-Customs coordination and protects confidential commercial information.
• Delays application to products manufactured and packaged five years after enactment.